Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR ...
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the European Medicines Agency (EMA) for ...
Morningstar6d
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Vutrisiran is also in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), which encompasses both wild-type and hereditary forms of the disease. Alnylam (Nasdaq ...
Alnylam Submits SNDA For Vutrisiran To Treat ATTR Amyloidosis With Cardiomyopathy
RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Wednesday the submission of its supplemental New Drug ...
AFP3d
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals ... an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA ...
Business Wire13d
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
Alnylam. “We believe that, pending regulatory approval, vutrisiran has the potential to become a first-line therapy for ATTR amyloidosis with cardiomyopathy. We look forward to working with the ...
Stockhouse5d
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Vutrisiran is also in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), which encompasses both wild-type and hereditary forms of the disease. Alnylam (Nasdaq: ALNY) has ...
Alnylam Pharma Submits Type II Variation To European Medicines Agency For Vutrisiran
Alnylam Pharmaceuticals (ALNY) announced the submission of a Type II Variation to the European Medicines Agency for vutrisiran, an ...
Investing12d
Alnylam files sNDA for new amyloidosis treatment
Alnylam Pharmaceuticals ... aimed at treating ATTR amyloidosis with cardiomyopathy (ATTR-CM). The company announced the news today, leveraging a Priority Review Voucher for an expedited FDA ...
Nasdaq4d
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
Please note that Alnylam already markets vutrisiran in the EU under the brand name Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or ...